Assertio Holdings FCF Conversion

What does Assertio Holdings do? Assertio Holdings, Inc. generates revenue through the sale of prescription medications in neurology, inflammation, and pain management. Its marketed products include Cambia (diclofenac potassium) oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO tablets, SPRIX Nasal Spray, VIVLODEX capsules, ZIPSOR Liquid filled capsules, and ZORVOLEX capsules. These products are sold to healthcare providers and pharmacies within the U.S. market. The company also develops and commercializes pipeline products such as Diclofenac Potassium for mild/moderate acute pain, Long-acting Cosyntropin for adrenal insufficiency diagnosis, and a liquid formulation of Diclofenac potassium for acute migraine attacks, targeting specialty and orphan medicine segments. Assertio focuses on neurology, inflammation, and pain medication markets, with its portfolio primarily serving U.S. healthcare systems. The company's pipeline emphasizes specialty and orphan medicines, aiming to address unmet medical needs. Its revenue streams are derived from both existing marketed products and future commercialization of pipeline candidates, with a strategic emphasis on high-value therapeutic areas. The firm’s product lineup includes both established medications and emerging therapies, with Diclofenac Potassium appearing in multiple formulations across different therapeutic applications. This dual approach allows Assertio to maintain steady revenue from current sales while building toward future growth through its pipeline development efforts. Assertio Holdings is one of the most popular companies on Eulerpool.